Terns Pharmaceuticals, Inc. (FRA:430)

Germany flag Germany · Delayed Price · Currency is EUR
30.00
-2.00 (-6.25%)
At close: Jan 9, 2026
-9.09%
Market Cap3.32B
Revenue (ttm)n/a
Net Income (ttm)-80.49M
Shares Outn/a
EPS (ttm)-0.88
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume400
Average Volume121
Open32.20
Previous Close32.00
Day's Range30.00 - 32.20
52-Week Range30.00 - 34.80
Betan/a
RSIn/a
Earnings DateMar 23, 2026

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic ... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Employees 59
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 430
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.